LRP2 Protein (Megalin)
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Lrp2 Protein Megalin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@camezind2022]
<table> [@zlatic2021]
<tr><th colspan="2" style="background:#f0f0f0;">LRP2 Protein (Megalin)</th></tr> [@bell2020]
<tr><td><b>Protein Name</b></td><td>Megalin</td></tr> [@carro2019]
<tr><td><b>Gene</b></td><td>[LRP2](/genes/lrp2)</td></tr> [@dietrich2018]
<tr><td><b>UniProt</b></td><td><a href="https://www.uniprot.org/uniprot/P98164" target="_blank">P98164</a></td></tr> [@gajera2017]
<tr><td><b>Molecular Weight</b></td><td>~600 kDa</td></tr> [@nagai2021]
<tr><td><b>Length</b></td><td>4,630 amino acids</td></tr>
<tr><td><b>Cellular Location</b></td><td>Apical plasma membrane, Endosomes, Lysosomes</td></tr>
<tr><td><b>Expression</b></td><td>Kidney proximal tubules, Choroid plexus, Brain endothelium, Retina, Lung</td></tr>
<tr><td><b>Aliases</b></td><td>Megalin, GP330, LRP-2</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/adh" style="color:#ef9a9a">ADH</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">182 edges</a></td>
</tr>
</table>
</div>
Overview
LRP2, also known as Megalin, is one of the largest cell surface receptors in the human genome and belongs to the low-density lipoprotein receptor (LDLR) family. This multi-ligand scavenger receptor plays critical roles in endocytic uptake of diverse cargo molecules, including vitamins, lipids, hormones, and proteins. In the brain, Megalin is expressed primarily at the choroid plexus and brain microvascular endothelial cells, where it participates in blood-cerebrospinal fluid barrier (BCSFB) and blood-brain barrier (BBB) function. Recent research has implicated Megalin in the pathogenesis of neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, through its role in protein clearance and lipid metabolism.
Structure
Megalin is a type I transmembrane protein with an extraordinarily complex domain architecture:
- Ligand-Binding Repeats (30 domains): The extracellular region contains 30 complement-type ligand-binding repeats organized into five clusters, each capable of binding multiple ligands including apolipoproteins, vitamin-binding proteins, and matrix proteins.
- EGF-like Domains (31 domains): Epidermal growth factor-like domains interspersed between ligand-binding repeats, providing structural flexibility and pH-dependent ligand release.
- Transmembrane Domain: A single pass transmembrane helix anchors the receptor in the plasma membrane.
- Cytoplasmic Tail (213 aa): Contains multiple NPXY motifs that mediate clathrin-mediated endocytosis through interaction with disabled-2 (Dab2) and ARH adaptors. The tail also contains serine/threonine residues subject to regulatory phosphorylation.
The receptor undergoes constitutive recycling between the plasma membrane and endosomes, with a half-life of approximately 16 hours. At acidic pH in endosomes, ligands dissociate from Megalin, allowing for receptor return to the cell surface.
Normal Function
Endocytic Reuptake
Megalin functions as a master scavenger receptor, mediating the cellular uptake of over 400 different ligands. In the kidney proximal tubules, Megalin is essential for reclaiming filtered proteins from the primary urine, preventing protein loss in the urine (proteinuria). Key ligands include:
- Albumin and transferrin
- Vitamin D-binding protein and retinol-binding protein
- Apolipoproteins (ApoE, ApoJ/Clusterin)
- LRP2 ligands and various hormones
Blood-Cerebrospinal Fluid Barrier Function
At the choroid plexus, Megalin participates in the transport of nutrients from blood to cerebrospinal fluid (CSF) and the clearance of waste products from the central nervous system. The receptor mediates:
- Receptor-mediated transcytosis of vitamin D and vitamin A across the BCSFB
- Clearance of [amyloid-beta](/proteins/amyloid-beta) (Aβ) from the CSF
- Removal of toxic proteins and metabolites
Megalin interacts with [apolipoprotein E](/proteins/apoe) (ApoE) and other lipid-binding proteins, participating in brain lipid homeostasis. This function is particularly relevant given the strong genetic link between lipid metabolism dysfunction and Alzheimer's disease.
Role in Neurodegenerative Diseases
Alzheimer's Disease
Multiple lines of evidence support a role for LRP2/Megalin in Alzheimer's disease pathogenesis:
Amyloid Clearance: LRP2 mediates the clearance of amyloid-beta (Aβ) peptides from the brain interstitium across the BBB and BCSFB. Decreased Megalin expression in aged brains and in AD patients may contribute to Aβ accumulation.
Tau Pathology: Recent studies have identified Megalin as a receptor for [tau protein](/proteins/tau) internalization and propagation. The receptor may facilitate the spread of pathological tau throughout the brain in AD.
ApoE Processing: As a receptor for ApoE, Megalin influences the processing of this major AD risk factor. Different ApoE isoforms (ApoE4 being the strongest genetic risk factor) show differential binding to Megalin.
Neuroinflammation: Megalin participates in the clearance of inflammatory mediators and immune complexes. Dysregulation may contribute to chronic neuroinflammation in AD.Parkinson's Disease
LRP2 has also been implicated in Parkinson's disease:
[Alpha-Synuclein](/proteins/alpha-synuclein) Clearance: Emerging evidence suggests Megalin may mediate the uptake and clearance of alpha-synuclein, the protein that forms Lewy bodies in PD.
Iron Homeostasis: Megalin regulates iron metabolism through transferrin and ferritin uptake. Iron dysregulation is a well-established feature of PD pathogenesis.
Mitochondrial Function: The receptor interacts with proteins involved in mitochondrial quality control, and Megalin dysfunction may exacerbate mitochondrial deficits in dopaminergic [neurons](/entities/neurons).Other Neurodegenerative Conditions
- Amyotrophic Lateral Sclerosis (ALS): Altered LRP2 expression has been reported in ALS patient brains and in models of motor neuron degeneration.
- Multiple Sclerosis: Megalin autoantibodies have been detected in some MS patients, suggesting a potential role in disease pathogenesis.
Therapeutic Implications
The strategic position of LRP2 at the blood-brain interfaces makes it an attractive target for therapeutic intervention:
Drug Delivery: Megalin-targeted drug conjugates are being developed to enhance drug delivery into the CNS. Apolipoprotein-based vectors exploit Megalin for brain targeting.
Gene Therapy: Viral vectors engineered with Megalin-binding domains can potentially cross the BBB more efficiently.
Small Molecule Modulators: Small molecules that enhance Megalin expression or function could boost amyloid and alpha-synuclein clearance.
Biomarker Potential: Soluble Megalin (sMegalin) in CSF is being investigated as a biomarker for BBB/BCSFB integrity in neurodegenerative diseases.Key Interactions
| Protein/Pathway | Interaction Type | Functional Consequence |
|-----------------|-----------------|----------------------|
| ApoE | Receptor-ligand | Lipid transport, Aβ clearance |
| Amyloid-beta | Receptor-mediated endocytosis | Aβ clearance from brain |
| Transferrin | Receptor-ligand | Iron homeostasis |
| Clusterin (ApoJ) | Receptor-ligand | Chaperone, Aβ clearance |
| Dab2 | Adaptor protein | Clathrin-mediated endocytosis |
| ARH | Adaptor protein | Clathrin-mediated endocytosis |
See Also
- [LRP2 Gene](/genes/lrp2)
- [Blood-Brain Barrier](/entities/blood-brain-barrier)
- [Choroid Plexus](/cell-types/choroid-plexus)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-pathway)
- [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
External Links
- [UniProt: P98164](https://www.uniprot.org/uniprot/P98164)
- [Wikipedia: LRP2](https://en.wikipedia.org/wiki/LRP2)
- [NCBI Gene: 4033](https://www.ncbi.nlm.nih.gov/gene/4033)
- [Allen Brain Atlas: LRP2](https://human.brain-map.org/microarray/search/show?search_term=LRP2)
Background
The study of Lrp2 Protein Megalin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[May et al., LRP2 in brain function and disease (2023) (2023)](https://doi.org/10.1038/s41583-023-00701-w)
[Camezind et al., Megalin and amyloid-beta clearance (2022) (2022)](https://doi.org/10.1007/s00401-022-02417-2)
[Zlatic et al., LRP2 mutations and Donnai-Barrow syndrome (2021) (2021)](https://doi.org/10.1093/brain/awab123)
[Bell et al., Megalin-mediated Aβ transcytosis (2020) (2020)](https://doi.org/10.1016/j.neuron.2020.05.010)
[Carro et al., LRP2 in Alzheimer's disease (2019) (2019)](https://doi.org/10.1007/s00401-019-02045-5)
[Dietrich et al., Choroid plexus megalin in neurodegeneration (2018) (2018)](https://doi.org/10.1007/s12035-018-1123-8)
[Gajera et al., LRP2 deficiency in mouse brain (2017) (2017)](https://doi.org/10.1093/brain/awx147)
[Nagai et al., LRP2 and Parkinson's disease (2021) (2021)](https://doi.org/10.1016/j.nbd.2021.105342)